PHILADELPHIA (PRWEB) August 11, 2022
InfraScan, a medical device firm specializing in traumatic brain injury diagnostic products, announced the publication of the largest U.S. study to date using a near-infrared device (NIRD) to detect bleeds resulting from Traumatic Brain Injuries (TBI). This independent study was published in the Journal of Neurotrauma on 2 Aug 2022. https://doi.org/10.1089/neu.2021.0342.
“We wish to thank Dr. Michael Haglund, Dr. Anthony Fuller, Dr. Robert Gramer, and the entire team at Duke Global Neurosurgery and Neurology for their superb work in TBI clinical research using near-infrared technology”, said Baruch Ben Dor, PhD, president, and CEO of InfraScan.
The Infrascanner is a portable, hand-held device that uses NIR technology to screen patients for intracranial bleeding, identifying those who would most benefit from neurosurgical intervention and may inform neurosurgical decision-making in settings where CT scanning is unavailable or impractical.
In addition to being independent, this is the largest U.S.-based Infrascanner study published to date with 500 TBI patients, including 104 of these with intracranial bleeds. For all bleeds, the Infrascanner demonstrated 86% sensitivity and 96% specificity. Equally as important, for bleeds within the detection capabilities of Infrascanner (bleeds of more than 3.5 mL), the sensitivity was 94% and the specificity 96%. In those patients who required surgical intervention, the device demonstrated 100% sensitivity.
InfraScan has over 1,000 devices deployed in the US and internationally, including with some of the world's leading neurotrauma and trauma experts. InfraScan also licensed a variety of patents that apply to hemorrhagic and ischemic stroke detection as well as brain hemorrhage monitoring.
About InfraScan, Inc.
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing portable brain scanners for head injury and stroke assessment based on near-infrared (NIR) technologies. The company has received funding from the U.S. Army Medical Materiel Development Activity, U.S. Marine Corps, Office of Naval Research, BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, Ben Franklin Technology Partners of Southeastern Pennsylvania, and the Philadelphia Industrial Development Corporation. For more information visit http://www.infrascanner.com and follow us @infrascanner.
Vice President of Business Development